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oluble vascular cell adhesion molecule-1 
(sVCAM-1) and intercellular adhesion 
molecule-1 (sICAM-1) have been shown 
to be elevated in patients with Graves’ 
disease and may play significant roles in the 
pathogenesis of the disease. The objective of this 
study was to measure the levels of sVCAM-1, 
sICAM-1, IL-6 and thyroid receptor stimulating 
antibodies (TRAb) in a cohort of hyperthyroid 
patients and determine their associations to thy-
roid hormones status, before and after 3 months 
therapy with carbimazole.  
Materials and Methods: Patients were given 
fixed daily dose of 20 mg carbimazole for 3 
months and blood samples were collected at 
baseline and end of the study. Thirty-eight pa-
tients were recruited from the Endocrine Clinic, 
Hospital Universiti Kebangsaan Malaysia, con-
sisting of 26 females and 12 males, age ranging 
from 16 to 65 years. Blood samples collected be-
fore and at end of study were analysed for TSH, 
Free T3, Free T4, thyroid receptor stimulating anti-
bodies (TRAb), sVCAM-1, sICAM-1 and IL-6. 
Results: TRAb level of ≤10 U/L was taken to be 
negative, while TR b level of >10 U/L was con-
sidered as positive. Twenty-six patients (68%) 
were TRAb positive (TRAb+) and 12 patients 
(30%) were TRAb negative (TRAb-). Median 
TRAb in TRAb+ patients was 23 U/L at baseline, 
declining to 16.7 U/L (p<0.001) in the third 3 
month. Serum sVCAM-1 levels were signifi-
cantly elevated in TRAb+ patients compared to 
TRAb- (860 versus 499 ng/mL, p<0.001). The level 
decreased significantly to 537 ng/mL with treat-
ment but remained higher than in TRAb- pa-
tients (p=0.003). Irrespective of TRAb status, all 
but one patient had elevated serum sICAM-1 
levels that remained unaffected by carbimazole 
therapy. In contrast, IL-6 levels of hyperthyroid 
patients were within the reference range of 1.4-14.1 
pg/mL. Baseline and post-treatment sVCAM-1, 
and not TRAb levels, were significantly corre-
lated to thyroid hormones. 
S
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Conclusion: Compared to other inflammatory 
markers, sVCAM-1 showed significant correla-
tion to thyroid stimulating antibodies and was 
most sensitive to changes in thyroid status. The 
significance of these findings in relation to 
Graves’ disease warrants further investigation. 
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Introduction 
Thyroid receptor stimulating antibodies 
(TRAbs) have been shown to be present in 
about 80 to 95% of patients with Graves’ dis-
ease (GD).1,2 Unlike thyroglobulin and thy-
roid peroxidase antibodies, which can also be 
found in patients with autoimmune thyroidi-
tis and normal subjects, TRAbs are disease 
specific. The action of TRAb is analogous to E-mail: nazaimoon@imr.gov.my 
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that of TSH: binding and activating TSH re-
ceptors on the surface of thyroid cells, caus-
ing increase in intracellular cyclic AMP, thy-
roid hypertrophy and hyperplasia, and the re-
sultant excess production of thyroxine.3 In 
more recent studies, however, adhesion 
molecules which are involved in cell-to-cell 
communications leading to cellular events 
such as the migration of lymphocytes and in-
duction of the autoimmune process, have 
been postulated to also play significant roles 
in the pathogenesis of GD. Patients with GD 
were found to have elevated circulating lev-
els of intercellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion mole-
cule-1 (VCAM-1)4-8 and the thyrocytes and 
endothelial cells showed increased expres-
sion of the molecules.9-13 The reason for the 
increase is not yet clear but is postulated to 
be either due to the activation of vascular en-
dothelium at non-related sites or a decrease in 
the metabolism of the adhesion molecules in 
thyrotoxicosis. 
The aim of this study was to determine the 
levels of VCAM-1, ICAM-1 and cytokine, 
interleukin-6 (IL-6) in patients with hyper-
thyroidism, and their associations to TRAb 
and thyroid hormones status following 3 
months of therapy with carbimazole. 
 
Materials and Methods 
 
Subjects 
A total of 38 patients were recruited from 
the Endocrine Clinic, Hospital Universiti Ke-
bangsaan Malaysia, Malaysia. There were 26 
females and 12 males, age ranging from 16 to 
65 years old, with a mean of 36.5 years. For 
the purpose of this study, only patients with 
mild to moderate thyrotoxicosis were re-
cruited; they were either newly diagnosed or 
if relapsed, has been in remission for at least 
6 months. All patients gave their informed 
consent to participate, and ethical approval 
for human use was obtained from the relevant 
body prior to the study. Patients were given 
carbimazole 20 mg daily and were clinically 
reviewed every month for 3 months. Blood 
samples were collected between 8.00 and 
10.00 h at the beginning and end of 3 months 
of therapy. Exclusion criteria included pa-
tients with active ophthalmopathy, inflamma-
tory disease, atrial fibrillation, severe thyro-
toxicosis, associated ovarian, adrenal, testicu-
lar or pituitary disease, renal disease, liver 
disease, hemolytic anaemia, prostate disease, 
bone disease, cardiac failure, pericarditis, hy-
pertension and arrhythmias not associated 
with thyroid disease, or those on drugs such 
as HRT, beta blockers and steroids. 
 
Assays 
Free T3 (fT3) and free T4 (fT4) were meas-
ured using kits purchased from Diagnostic 
Products Corporation, Los Angeles, CA 
90045-5597. The reference ranges quoted for 
fT3 and fT4 were between 2.2-6.8 and 10.3-
25.7 pmol/L, respectively. Intra- and interas-
say coefficient of variations (CVs) for both 
hormones were within 5% and 7-9%, respec-
tively. Serum TSH was determined by micro 
particle enzyme immunoassay (MEIA) from 
Abbott Laboratories, USA. Mean assay sensi-
tivity was 0.04 uIU/mL, and both intra- and 
interassay CVs were <10%. The reference 
range for TSH was 0.47-5.0 uIU/mL. 
The TRAb kit was purchased from Di-
aSorin, Stillwater, Minnesota 55082-0285, 
USA. The assay has been calibrated against 
the WHO LATS-B (MRC 65/122) and for the 
purpose of this study, a TRAb level of ≤10 
U/L was taken to be negative, while a level 
of >10 U/L was considered as positive for 
TRAb. Interassay CV at 12 and 56 U/L was 
8.6 and 13% respectively. 
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The enzyme immunoassay kits for human 
soluble VCAM-1 (sVCAM-1), soluble 
ICAM-1 (sICAM-1) and IL-6 ELISA were 
purchased from MedSystems Diagnostics 
GmbH, Rennweg 95b, Vienna, Austria. To 
reduce variability in results, samples col-
lected from each patient were analysed in a 
single assay.  
 
Statistics 
Data were analysed by SAS statistical 
package, using non-parametric analysis of 
variance. Differences between groups were 
compared using Wilcoxon rank sum test and 
correlation between thyroid hormones and 
TRAb and adhesion molecules was evaluated 
by Spearman’s Correlation test. Unless oth-
erwise stated, all results are expressed as me-
dian and 95% confidence interval (CI). A p 
value of less than 0.05 was considered as sig-
nificant. 
 
Results 
The overall median and 95% CI levels of 
thyroid hormones at baseline and at the end 
of the study are as shown in Table 1. At 
month 3,7 (18.5%) patients were still hyper-
thyroid, 16 (42.1%) were subclinically hyper-
thyroid as indicated by their suppressed TSH 
but normalised thyroid hormones, 11 (28.9%) 
become euthyroid, and 4 (10.5%) had actu-
ally become hypothyroid. 
Data were also analysed according to the 
TRAb status (Table 2). About 68% (26/38) of 
patients had TRAb levels above 10 U/L 
(TRAb+) while the remaining 30% (12/38) 
were negative (TRAb-). Median TRAb value 
in TRAb+ patients was 23 U/L at baseline, 
declining to 16.7 U/L (p<0.001) at month 3. 
Serum sVCAM-1 levels were significantly 
elevated in TRAb+ patients compared to 
those who were negative to TRAb (860 ver-
sus 499 ng/mL, p<0.001). The level de-
creased significantly to 537 ng/mL with 
treatment but remained higher than in TRAb- 
patients (p=0.003). In contrast, irrespective of 
their TRAb status, all but one patient had sI-
CAM-1 level that was significantly higher 
than the quoted reference range of 115-306 
ng/mL. The levels were not affected by car-
bimazole therapy. However, hyperthyroidism 
has no effect on IL-6; the levels remained 
within the reference range of 1.4-14.1 pg/mL 
and were not affected by carbimazole.  
 
 
 
Table 1. Thyroid hormone profile (median and 95 % Confidence Interval) of patients before and after  
3 months of carbimazole therapy  
 
 Free T4 (pmol/L) Free T3 (pmol/L) TSH (mIU/L) 
Reference range  10.3 – 26.0 2.2 – 6.8 0.47 – 5.0 
Baseline (n = 38) 46.5 (27 – 77) 22.0 (6.3 – 46) 0.01 (0.01 – 0.02) 
Month 3 (n = 38) 11.8 (7 – 66) 3.8 (2.4 – 27) 0.1 (0.1 – 8.4) 
Numbers represent median (95% CI). 
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Table 2. Medians (and 95% CI) of thyroid hormones, sVCAM-1, sICAM-1 and IL-6 of TRAb+ and 
TRAb- patients before and after 3 months of carbimazole therapy 
 
 Visit TRAb + (>10 U/L, n = 26) TRAb – (≤ 10 U/L, n = 12) 
Baseline 50 (33 - 77) 38 (27 - 56) Free T4  (pmol/L) 
Month 3 12.9 (7 - 66)* 10.7 (7 - 27)*
Baseline 26 (6.3 - 46) 12.1 (6.4 - 22.4) Free T3  (pmol/L) 
Month 3 4.6 (2.9 - 27)* 3.5 (2.1 - 8.3)*
Baseline 0.1 (0.1 - 0.1) 0.1 (0.1 - 0.1) TSH  (mU/L) 
Month 3 0.1 (0.1 - 8.4)* 0.8 (0.1 - 5)*
Baseline 860 (640 – 1262) 499 (335 - 897) VCAM-1(ng/mL) 
Month 3 537 (335 - 886)*† 388 (208 - 606)*
Baseline 798 (356 – 1109) 559 (266- 919) ICAM (ng/mL) 
Month3 648 (407 - 950) 607 (268 – 997) 
Baseline 1.4(1.4 - 6.2) 1.4 (1.4 –3.5) IL-6 (pg/mL) 
Month 3 1.4 (1.4 – 7)  1.4 (1.4 – 2.4) 
Numbers represent median (95% CI). 
*p<0.001 versus pre-treatment, † p=0.003 versus respective TRAb- patients. 
 
 
As expected, fT3 and fT4 were significantly 
higher in TRAb+ patients (p<0.001) but fol-
lowing therapy, the levels decreased to a me-
dian value of 12.9 pmol/L which was not sig-
nificantly different from that obtained in 
TRAb- patients (10.7 pmol/L, Table 3). Of 
the 19 patients (73%) who remained positive 
to TRAb at month 3, 15 (78.9%) were still ei-
ther hyperthyroid or subclinically hyperthy-
roid, 2, were (10.5%) in remission while the 
remainding 2 patients (10.5%) had became 
hypothyroid.  
There was no significant association ob-
served between thyroid hormones and TRAb 
levels amongst patients with detectable 
TRAb prior to therapy and in those who re-
mained positive following 3 months of car-
bimazole. In contrast, sVCAM-1 in TRAb+ 
patients showed positive correlation to base-
line fT3 (r=0.465, p=0.02, Fig. 1) and the as-
sociations were found to be more significant 
in patients who remained TRAb+ despite 
therapy (Figs. 2 and 3). No significant corre-
lation was observed between sICAM-1 or IL-
6 and the thyroid hormones in either group of 
patients. 
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Fig. 1. Correlation between free T3 and 
sVCAM-1 in TRAb+ patients before carbima-
zole therapy 
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Fig. 2. Correlation between Free T4 and 
sVCAM-1 in post-carbimazole TRAb+ patients 
 
 
Fig. 3. Correlation between Free T3 and 
sVCAM-1 in post- carbimazole TRAb+  
patients 
 
 
Discussion 
Several studies have suggested that TRAb 
measurement is useful in the diagnosis and 
management of Graves’ disease. Presence of 
TRAb is normally associated with relapse,14-18 
and such patients would benefit from contin-
ued treatment.19,20 Others however, found lit-
tle predictive value in such measurement and 
believed that the test should only be carried 
out when the etiology of the hyperthyroid 
state could not be determined.21-23 In those 
studies, not all patients who relapsed were 
positive to TRAb and likewise, there were 
also patients who, despite having presented 
with detectable TRAb, remained in remission 
after the antithyroid therapy.24,25 Similarly in 
this study, of the 19 patients who remained 
TRAb+ after 3 months therapy, 2 were euthy-
roid and another 2 had actually become hypo-
thyroid, thus indicating that the normalization 
of the thyroid hormones was mainly caused 
by carbimazole, and whether the patient re-
lapses or remains in remission cannot be at-
tributed solely to the presence or absence of 
TRAb. On the other hand, such controversy 
may partly be due to the different assay sys-
tems used, whether bioassay or radioreceptor, 
leading to differences in assay sensitivity. 
The significance of adhesion molecules as 
mediators of events during inflammatory re-
sponse has been described in many studies. 
Malignancies and autoimmune disorders in-
cluding rheumatoid arthritis and Graves’ oph-
thalmopathy were shown to be associated 
with increased expression of ICAM-1, 
VCAM-1 and selectins.7,26,27 ICAM-1 and 
VCAM-1 are type-1 transmembrane glyco-
proteins transiently expressed on activated 
vascular endothelial cells in response to vas-
cular endothelial growth factor and other cy-
tokines, such as TNF-α, interleukin-1β, and 
interferon.28 VCAM-1 can be detected in the 
circulation although the exact mechanism by 
which it is shredded into the bloodstream is 
unknown.29 The markedly elevated sVCAM-1 
seen amongst TRAb+ patients was similarly 
reported by Wenisch et al.6 Compared to 
ICAM or IL-6, carbimazole therapy caused 
significant decrease in sVCAM-1, in parallel 
to decrease in fT3 and fT4, implying, unlike 
other inflammatory markers, sVCAM-1 is 
more sensitive to changes in thyroid status 
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and perhaps, to changes associated with the 
inflammation process. There is no doubt that 
more useful data would have been obtained if 
this study had been continued to include as-
sessment of disease outcome and the signifi-
cance of sVCAM-1 compared to that of 
TRAb. 
In contrast to several earlier reports,8,12,26 
sICAM-1 remained elevated and was not af-
fected by carbimazole therapy. The absence 
of any change could probably be explained 
by the fact that ICAM-1 is more associated 
with inflammatory activity where levels were 
reported to increase before the onset of clini-
cal ophthalmology.26 In this study, active 
ophthalmopathy was one of the exclusion cri-
teria used. On the other hand, these observa-
tions could be due to differences in tissue dis-
tributions of the adhesion molecules or varia-
tions in the biological half-lives according to 
disease conditions.21,30,31 We confirmed the 
report by Wenisch et al, that thyroid status 
has no effect on IL-6; the levels remained 
within the normal range throughout the study 
duration.6
In conclusion, despite its many limitations, 
this study showed that Graves’ disease is in-
deed a multi-systemic inflammatory disease, 
affecting not only the thyroid gland but also 
other tissues such as those associated with 
immune response and inflammation. Since 
the usefulness of TRAb as adjunct prognostic 
marker for Graves’ disease is still debatable, 
it may therefore be worthwhile to further 
evaluate the clinical significance of sVCAM-1 
and its potential use as an alternative marker. 
Such study should include long-term follow-
up and monitoring of patients, and evaluating 
sVCAM-1 levels in those who remained in 
remission and comparison with those who 
later relapsed. 
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